Literature DB >> 9990329

Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration.

J J Plantner1, C Jiang, A Smine.   

Abstract

Matrix metalloproteinases have increasingly been shown to be associated with diseases involving neovascularization and/or abnormal cellular migration or proliferation. A number of diseases of this type affect the retina. In this study, the activity of gelatinase A (MMP-2), the most abundant matrix metalloproteinase in IPM (interphoto receptor matrix) and vitreous, was measured with respect to age in normal human donor eyes and compared to donors with age-related macular degeneration. IPM and vitreous were obtained from a total of 88 human donors. Samples for electrophoresis were normalized for protein content and subjected to quantitative gelatin zymography. The zymograms were scanned and then digitized and quantitated using the NIH 'Image' program. There was not a statistically significant change in the level of gelatinase A in IPM or vitreous as a function of age, although a slight downward trend was found in the total gelatinase A activity within the normal population. Likewise, when comparing normal and age-related macular degeneration donors, there was not a significant difference in the gelatinase A level in vitreous or in retina-associated IPM. However, the level of gelatinase A was nearly doubled specifically in retinal pigment epithelium-associated IPM from eyes with age-related macular degeneration [0.99 +/- 0.09 U mg-1 (56) vs 1.71 +/- 0.28 U mg-1 (14) (mean +/- S.E.M. (number), P < 0.0021; 1 unit = 1.0 ng gelatin cleaved h-1). Gelatinase A may be associated with the changes that occur in age-related macular degeneration, especially the neovascularization which accompanies the exudative ('wet') form of the disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9990329     DOI: 10.1006/exer.1998.0552

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  26 in total

Review 1.  Matrix metalloproteinase biology applied to vitreoretinal disorders.

Authors:  C S Sethi; T A Bailey; P J Luthert; N H Chong
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

2.  Expression and distribution of matrix metalloproteinases and their inhibitors in the human iris and ciliary body.

Authors:  J Lan; R K Kumar; N Di Girolamo; P McCluskey; D Wakefield
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

3.  Expression of matrix metalloproteinases in the subretinal fluid correlates with the extent of rhegmatogenous retinal detachment.

Authors:  Chrysanthos Symeonidis; Eudoxia Diza; Eleni Papakonstantinou; Efimia Souliou; George Karakiulakis; Stavros A Dimitrakos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-08-29       Impact factor: 3.117

4.  Oxidised, glycated LDL selectively influences tissue inhibitor of metalloproteinase-3 gene expression and protein production in human retinal capillary pericytes.

Authors:  J L Barth; Y Yu; W Song; K Lu; A Dashti; Y Huang; W S Argraves; T J Lyons
Journal:  Diabetologia       Date:  2007-08-04       Impact factor: 10.122

Review 5.  Mediators of ocular angiogenesis.

Authors:  Yureeda Qazi; Surekha Maddula; Balamurali K Ambati
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

Review 6.  Delta Opioids: Neuroprotective Roles in Preclinical Studies.

Authors:  Shahid Husain
Journal:  J Ocul Pharmacol Ther       Date:  2018 Jan/Feb       Impact factor: 2.671

7.  Angiotensin II-induced MMP-2 activity and MMP-14 and basigin protein expression are mediated via the angiotensin II receptor type 1-mitogen-activated protein kinase 1 pathway in retinal pigment epithelium: implications for age-related macular degeneration.

Authors:  Marianne Pons; Scott W Cousins; Oscar Alcazar; Gary E Striker; Maria E Marin-Castaño
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

Review 8.  Metalloproteinases as mediators of inflammation and the eyes: molecular genetic underpinnings governing ocular pathophysiology.

Authors:  Mahavir Singh; Suresh C Tyagi
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

9.  Chemokine CXCL-1: activity in the vitreous during proliferative vitreoretinopathy.

Authors:  C Symeonidis; S Androudi; I Georgalas; A Tzamalis; N Chalvatzis; T Rotsos; E Souliou; E Diza; S A Dimitrakos
Journal:  Clin Exp Immunol       Date:  2015-08       Impact factor: 4.330

10.  Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy.

Authors:  Olcay Tatar; Annemarie Adam; Kei Shinoda; Tillmann Eckert; Gábor B Scharioth; Micheal Klein; Efdal Yoeruek; Karl Ulrich Bartz-Schmidt; Salvatore Grisanti
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.